Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph W Chow

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|March 26, 2003
Multiplex PCR for detection of aminoglycoside resistance genes in enterococciSergei B Vakulenko, Susan M Donabedian, Anatoliy M Voskresenskiy, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2020
<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical TrialGregory G Stone, Patricia A Bradford, Margaret Tawadrous, et al.
The Journal of Antimicrobial Chemotherapy|June 19, 2018
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programmeGregory G Stone, Paul Newell, Leanne B Gasink, et al.
Infectious Diseases and Therapy|November 21, 2025
Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam-Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against EnterobacteralesSusan R Raber, Rujia Xie, Halley Rogers, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|March 3, 2006
Purification, crystallization and preliminary X-ray analysis of Enterococcus faecium aminoglycoside-2''-phosphotransferase-Ib [APH(2'')-Ib]Rupa Walanj, Paul Young, Heather M Baker, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2002
Molecular analysis of vancomycin-resistant Enterococcus faecalis from Michigan hospitals during a 10 year periodPreeti N Malani, LeeAnn Thal, Susan M Donabedian, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotypeSusan E Flannagan, Joseph W Chow, Susan M Donabedian, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Structures, locations, and transfer frequencies of genetic elements conferring high-level gentamicin resistance in Enterococcus faecalis isolates in GreeceGeorge L Daikos, George Bamias, Christos Kattamis, et al.
Infectious Diseases and Therapy|August 10, 2021
Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial ProgramJohn E Mazuski, Florian Wagenlehner, Antoni Torres, et al.
The Lancet. Infectious Diseases|December 20, 2017
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trialAntoni Torres, Nanshan Zhong, Jan Pachl, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|March 26, 2003
Multiplex PCR for detection of aminoglycoside resistance genes in enterococciSergei B Vakulenko, Susan M Donabedian, Anatoliy M Voskresenskiy, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2020
<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical TrialGregory G Stone, Patricia A Bradford, Margaret Tawadrous, et al.
The Journal of Antimicrobial Chemotherapy|June 19, 2018
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programmeGregory G Stone, Paul Newell, Leanne B Gasink, et al.
Infectious Diseases and Therapy|November 21, 2025
Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam-Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against EnterobacteralesSusan R Raber, Rujia Xie, Halley Rogers, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|March 3, 2006
Purification, crystallization and preliminary X-ray analysis of Enterococcus faecium aminoglycoside-2''-phosphotransferase-Ib [APH(2'')-Ib]Rupa Walanj, Paul Young, Heather M Baker, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2002
Molecular analysis of vancomycin-resistant Enterococcus faecalis from Michigan hospitals during a 10 year periodPreeti N Malani, LeeAnn Thal, Susan M Donabedian, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotypeSusan E Flannagan, Joseph W Chow, Susan M Donabedian, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2003
Structures, locations, and transfer frequencies of genetic elements conferring high-level gentamicin resistance in Enterococcus faecalis isolates in GreeceGeorge L Daikos, George Bamias, Christos Kattamis, et al.
Infectious Diseases and Therapy|August 10, 2021
Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial ProgramJohn E Mazuski, Florian Wagenlehner, Antoni Torres, et al.
The Lancet. Infectious Diseases|December 20, 2017
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trialAntoni Torres, Nanshan Zhong, Jan Pachl, et al.
Pageof 4